These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11815975)

  • 1. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.
    Rocha Lima CM; Herndon JE; Kosty M; Clamon G; Green MR
    Cancer; 2002 Jan; 94(1):181-7. PubMed ID: 11815975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
    Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
    J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older.
    Battisti NML; Sehovic M; Extermann M
    Clin Lung Cancer; 2017 Sep; 18(5):460-471. PubMed ID: 28416124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
    Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
    Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials.
    Clarey J; Kao SC; Clarke SJ; Vardy J
    Ann Oncol; 2012 May; 23(5):1229-1233. PubMed ID: 21986095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
    Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
    Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non–small-cell lung cancer in elderly patients: a discussion of treatment options.
    Gajra A; Jatoi A
    J Clin Oncol; 2014 Aug; 32(24):2562-9. PubMed ID: 25071101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
    Wheatley-Price P; Le Maître A; Ding K; Leighl N; Hirsh V; Seymour L; Bezjak A; Shepherd FA;
    J Thorac Oncol; 2010 May; 5(5):640-8. PubMed ID: 20354457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
    Breathnach OS; Freidlin B; Conley B; Green MR; Johnson DH; Gandara DR; O'Connell M; Shepherd FA; Johnson BE
    J Clin Oncol; 2001 Mar; 19(6):1734-42. PubMed ID: 11251004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and treatment of non-small-cell lung cancer: a database analysis in elderly patients.
    Berghmans T; Tragas G; Sculier JP
    Support Care Cancer; 2002 Nov; 10(8):619-23. PubMed ID: 12436220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials.
    Horn L; Keedy VL; Campbell N; Garcia G; Hayes A; Spencer B; Carbone DP; Sandler A; Johnson DH
    Clin Lung Cancer; 2013 Jan; 14(1):14-8. PubMed ID: 22591607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.
    Kimmick GG; Peterson BL; Kornblith AB; Mandelblatt J; Johnson JL; Wheeler J; Heinze R; Cohen HJ; Muss HB
    J Clin Oncol; 2005 Apr; 23(10):2201-7. PubMed ID: 15800312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
    Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
    Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?
    Sacher AG; Le LW; Leighl NB; Coate LE
    J Thorac Oncol; 2013 Mar; 8(3):366-8. PubMed ID: 23407560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the randomized phase III trials in non-small cell lung cancer in North America.
    Kelly K
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-2-S8-5. PubMed ID: 9207308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials.
    Jennens RR; Giles GG; Fox RM
    Intern Med J; 2006 Apr; 36(4):216-20. PubMed ID: 16640737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients?
    Alsan Cetin I; Akgun Z; Atasoy BM; Fulden Yumuk P; Abacioglu U
    J BUON; 2013; 18(2):453-8. PubMed ID: 23818361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.